OA10730A - Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens - Google Patents

Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens Download PDF

Info

Publication number
OA10730A
OA10730A OA60952A OA60952A OA10730A OA 10730 A OA10730 A OA 10730A OA 60952 A OA60952 A OA 60952A OA 60952 A OA60952 A OA 60952A OA 10730 A OA10730 A OA 10730A
Authority
OA
OAPI
Prior art keywords
estrogen
regimen
effective
level
antagonist
Prior art date
Application number
OA60952A
Other languages
English (en)
Inventor
Gary D Hodgen
Audrey Philips
Original Assignee
Hampton Roads Medical College
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by Hampton Roads Medical College, Ortho Pharma Corp filed Critical Hampton Roads Medical College
Publication of OA10730A publication Critical patent/OA10730A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA60952A 1994-07-22 1997-01-13 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens OA10730A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (1)

Publication Number Publication Date
OA10730A true OA10730A (en) 2001-06-07

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60952A OA10730A (en) 1994-07-22 1997-01-13 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Country Status (29)

Country Link
EP (1) EP0769956B1 (xx)
JP (1) JP3138477B2 (xx)
CN (1) CN1137722C (xx)
AP (1) AP775A (xx)
AT (1) ATE190494T1 (xx)
AU (1) AU691952B2 (xx)
BG (1) BG63363B1 (xx)
BR (1) BR9508718A (xx)
CA (1) CA2195745C (xx)
CY (1) CY2228B1 (xx)
CZ (1) CZ291803B6 (xx)
DE (1) DE69515666T2 (xx)
DK (1) DK0769956T3 (xx)
EE (1) EE03515B1 (xx)
ES (1) ES2145286T3 (xx)
FI (1) FI970244A (xx)
GR (1) GR3033590T3 (xx)
HU (1) HU218910B (xx)
IL (1) IL114655A (xx)
IS (1) IS4413A (xx)
LV (1) LV11823B (xx)
MX (1) MX9700574A (xx)
NO (1) NO970257L (xx)
NZ (1) NZ290554A (xx)
OA (1) OA10730A (xx)
PT (1) PT769956E (xx)
RU (1) RU2181598C2 (xx)
SK (1) SK282118B6 (xx)
WO (1) WO1996003138A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
UA73956C2 (en) * 1999-09-23 2005-10-17 Zentaris Gmbh Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
ES2753539T3 (es) * 2015-05-18 2020-04-13 Nerre Therapeutics Ltd Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CZ291803B6 (cs) 2003-06-18
CN1200674A (zh) 1998-12-02
IL114655A (en) 2005-08-31
CA2195745C (en) 2005-03-29
JPH10503203A (ja) 1998-03-24
BR9508718A (pt) 1997-12-30
MX9700574A (es) 1997-12-31
HUT77127A (hu) 1998-03-02
WO1996003138A1 (en) 1996-02-08
HU9700046D0 (en) 1997-02-28
FI970244A0 (fi) 1997-01-21
CN1137722C (zh) 2004-02-11
AP9700913A0 (en) 1997-01-31
ES2145286T3 (es) 2000-07-01
CY2228B1 (en) 2003-04-18
EP0769956B1 (en) 2000-03-15
FI970244A (fi) 1997-01-21
DK0769956T3 (da) 2000-06-05
RU2181598C2 (ru) 2002-04-27
LV11823A (lv) 1997-08-20
IL114655A0 (en) 1995-11-27
DE69515666D1 (de) 2000-04-20
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
ATE190494T1 (de) 2000-04-15
JP3138477B2 (ja) 2001-02-26
BG63363B1 (bg) 2001-11-30
AU3132095A (en) 1996-02-22
PT769956E (pt) 2000-07-31
IS4413A (is) 1997-01-14
EE9700208A (et) 1998-02-16
BG101158A (en) 1997-09-30
SK7097A3 (en) 1997-11-05
EE03515B1 (et) 2001-10-15
AP775A (en) 1999-10-28
LV11823B (en) 1998-03-20
NZ290554A (en) 2000-08-25
NO970257D0 (no) 1997-01-21
HU218910B (hu) 2000-12-28
EP0769956A1 (en) 1997-05-02
AU691952B2 (en) 1998-05-28
DE69515666T2 (de) 2000-07-06
NO970257L (no) 1997-01-21
CA2195745A1 (en) 1996-02-08
SK282118B6 (sk) 2001-11-06
CZ15097A3 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
Murphy et al. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect
AU689229B2 (en) Treatment of ovarian estrogen dependent conditions
Wallach et al. Induction of ovulation with clomiphene citrate
US8450299B2 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
US5468736A (en) Hormone replacement therapy
Schriock et al. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin)
AU676523B2 (en) Compositions and methods of effecting contraception and control of breast cancer
WO2006042021A2 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Gordon Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy
OA10730A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Bygdeman et al. Contraceptive use of antiprogestin
US5658884A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Tiitinen et al. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism
Bergquist et al. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women
Gudmundsson et al. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH
Ushiroyama et al. Estrogen replacement therapy in postmenopausal women: a study of the efficacy of estriol and changes in plasma gonadotropin levels
Reid et al. LHRH agonists and antagonists: therapeutic possibilities for premenstrual syndrome